TY - JOUR
T1 - Minimally invasive pancreatic resections
T2 - cost and value perspectives
AU - the Minimally Invasive Pancreatic Resection Organizing Committee
AU - Conlon, Kevin C.
AU - de Rooij, Thijs
AU - van Hilst, Jony
AU - Abu Hidal, Mohammad
AU - Fleshman, Julie
AU - Talamonti, Mark
AU - Vanounou, Tsafrir
AU - Garfinkle, Richard
AU - Velanovich, Vic
AU - Kooby, David
AU - Vollmer, Charles M.
AU - Asbun, Horacio J.
AU - Barkun, Jeffrey
AU - Besselink, Marc G.H.
AU - Boggi, Ugo
AU - Han, Ho Seong
AU - Hansen, Paul D.
AU - Kendrick, Michael L.
AU - Kooby, David A.
AU - Montagnini, Andre L.
AU - Palanivelu, C.
AU - Røsok, Bård I.
AU - Shrikhande, Shailesh V.
AU - Wakabayashi, Go
AU - Zeh, Herbert
N1 - Publisher Copyright:
© 2017 International Hepato-Pancreato-Biliary Association Inc.
PY - 2017/3/1
Y1 - 2017/3/1
N2 - Background The number of minimally invasive pancreatic resections (MIPR) performed for benign or malignant disease, have increased in recent years. However, there is limited information regarding cost/value implications. Methods An international conference evaluating MIPR was held during the 12th Bi-Annual International Hepato-Pancreato-Biliary Association (IHPBA) World Congress in Sao Paulo, Brazil, on April 20th, 2016. This manuscript summarizes the presentations that reviewed current topics in cost and value as they pertain to MIPR. Results Compared to the open approach, MIPR's are associated with higher operative costs but lower postoperative costs. However, measurements of patient value (defined as improvement in both quantity and quality of life) and financial value (using incremental cost-effectiveness ratio) are required to determine the true value at societal level. Conclusion Challenges remain as to how the potential benefits, both to the patient and the healthcare system as a whole, are measured. Research comparing MIPR versus other techniques for pancreatectomy will require appropriate and valid measurement tools, some of which are yet to be refined. Nonetheless, the experience to date would support the continued development of MIPR by experienced surgeons in high-volume pancreatic centers, married with appropriate review and recalibration.
AB - Background The number of minimally invasive pancreatic resections (MIPR) performed for benign or malignant disease, have increased in recent years. However, there is limited information regarding cost/value implications. Methods An international conference evaluating MIPR was held during the 12th Bi-Annual International Hepato-Pancreato-Biliary Association (IHPBA) World Congress in Sao Paulo, Brazil, on April 20th, 2016. This manuscript summarizes the presentations that reviewed current topics in cost and value as they pertain to MIPR. Results Compared to the open approach, MIPR's are associated with higher operative costs but lower postoperative costs. However, measurements of patient value (defined as improvement in both quantity and quality of life) and financial value (using incremental cost-effectiveness ratio) are required to determine the true value at societal level. Conclusion Challenges remain as to how the potential benefits, both to the patient and the healthcare system as a whole, are measured. Research comparing MIPR versus other techniques for pancreatectomy will require appropriate and valid measurement tools, some of which are yet to be refined. Nonetheless, the experience to date would support the continued development of MIPR by experienced surgeons in high-volume pancreatic centers, married with appropriate review and recalibration.
UR - http://www.scopus.com/inward/record.url?scp=85014149874&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85014149874&partnerID=8YFLogxK
U2 - 10.1016/j.hpb.2017.01.019
DO - 10.1016/j.hpb.2017.01.019
M3 - Article
C2 - 28268161
AN - SCOPUS:85014149874
SN - 1365-182X
VL - 19
SP - 225
EP - 233
JO - HPB
JF - HPB
IS - 3
ER -